According to one source , diverse categories of preclinical or early-stage clinical research for developing COVID‑19 therapeutic candidates included:
antibodies (61 candidates)
antivirals (22 candidates)
cell-based compounds (15 candidates)
RNA-based compounds (6 candidates)
scanning compounds to be repurposed (18 candidates)
various other therapy categories, such as anti-inflammatory, antimalarial, interferon, protein-based, antibiotics, and receptor-modulating compounds, among numerous others (86 candidates) for a total of 293 compounds under development in May
10 countries, Russia? Taiwan?